Scroll To Top
Health

Study shows Reyataz has low lipid side effects

Study shows Reyataz has low lipid side effects

We need your help
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.

A study of the recently approved protease inhibitor Reyataz shows that the medication is significantly less likely to boost blood-based lipid levels than similar medications, HIVandHepatitis.com reports. Previous studies have linked protease inhibitors with increases in cholesterol and triglyceride levels, which can put HIV-positive people at a higher risk for cardiac complications. A comparative study of Reyataz and Viracept among treatment-naive subjects showed that while both drugs lowered blood-based HIV viral levels, Reyataz was significantly less likely to boost LDL cholesterol and triglyceride levels. Although the long-term clinical significance of the lipid findings is still unknown, the study authors, writing in the journal AIDS, conclude that Reyataz "is a potent, safe, well-tolerated, and effective once-daily protease inhibitor with low pill burden."

Pride of Broadway Special

From our Sponsors

Most Popular

Latest Stories

Outtraveler Staff